To view or add a comment, sign in Top 10 diabetes drugs by sales TOP 2: Jardiance (Empagliflozin) 2023 Sales: $10.73 Billion Company: Boehringer Ingelheim/Eli Lilly FDA First Approval: August 1, 2014 Indications: Type 2 diabetes, chronic heart failure, chronic kidney disease In 2023, Jardiance accounted for 28.8% of Boehringer Ingelheim's net sales, making it the top-performing product
The neuroprotective potential of GLP-1 has been established in models of neurodegenerative disorders, including Parkinsons disease and Alzheimers disease (AD), with evidence suggesting it can modify disease progression and ameliorate pathology [29,30,31,32]
- B sung nng lng cho c th
Despite the potential risk, NAION remains relatively uncommon compared to the benefits provided by these medications